Revolutionary blood test for ME / Chronic Fatigue unveiled

Revolutionary blood test for ME / Chronic Fatigue unveiled

Peer reviewed – Experimental study – Human DNA

Scientists at the University of East Anglia and Oxford Biodynamics have developed a high accuracy blood test to diagnose Chronic Fatigue Syndrome, also known as Myalgic Encephalomyelitis (ME/CFS).

The debilitating long-term illness affects millions worldwide - including over 400,000 sufferers in the UK - but is poorly understood and has long lacked reliable diagnostic tools.

With 96 per cent accuracy, the test offers new hope for those living with the condition - which is often misunderstood and misdiagnosed.

And it is hoped that the breakthrough could pave the way for a similar blood test to diagnose long Covid.

Lead researcher Prof Dmitry Pshezhetskiy, from UEA's Norwich Medical School, said: “ME/CFS is a serious and often disabling illness characterised by extreme fatigue that is not relieved by rest.

“We know that some patients report being ignored or even told that their illness is ‘all in their head’.

“With no definitive tests, many patients have gone undiagnosed or misdiagnosed for years.

“We wanted to see if we could develop a blood test to diagnose the condition – and we did!

“Our discovery offers the potential for a simple, accurate blood test to help confirm a diagnosis, which could lead to earlier support and more effective management.”

"Post-Covid syndrome, commonly referred to as long Covid, is one example of ME/CFS, where a similar cluster of symptoms is triggered by the Covid-19 virus, rather than by other known causes such as glandular fever. We therefore hope that our research will also help pave the way for a similar test to accurately diagnose long Covid.”

How the discovery was made

The team used advanced EpiSwitch® 3D Genomics technology from Oxford BioDynamics (AIM:OBD) to see how DNA is folded in blood samples from 47 patients with severe ME/CFS and 61 healthy controls.

Each of our cells contains about two metres of DNA, packed tightly and folded in 3D. These folds aren’t random - millions of them are deliberate, forming a hidden code that helps turn genes on or off to keep us healthy.

OBD Chief Scientific Officer, Alexandre Akoulitchev, said: “Chronic Fatigue Syndrome is not a genetic disease you’re born with. That’s why using EpiSwitch ‘epigenetic’ markers - which can change during a person’s life, unlike fixed genetic code - was key to reaching this high level of accuracy.

“The EpiSwitch platform behind this test, together with OBD’s vast 3D Genomic knowledgebase, has already been proven to deliver practical, rapid blood diagnostics accessible at scale.

“With this breakthrough, we are proud to enable a first-in-class test that can address an unmet need for a quick and reliable diagnostic for a complex, challenging-to-identify illness.”

This approach using EpiSwitch has previously shown success in identifying disease-specific blood markers in highly complex inflammatory and neurological conditions such as fast ALS (amyotrophic lateral sclerosis), rheumatoid arthritis, and certain cancers. This includes the EpiSwitch PSE test, which is a blood test with world-leading accuracy for prostate cancer already used in the UK and US.

The team discovered a unique pattern that appears consistently in people with ME/CFS that is not seen in healthy people.

Using a different approach, this work looked beyond the linear DNA sequence investigated by a previously published DecodeME study, the largest genetic investigation of ME/CFS to date^‡.

By examining 3D genomic folds, UEA and Oxford BioDynamics revealed hundreds of additional changes, including five of the eight sites identified by DecodeME, which can now provide a deeper understanding of the disease.

The analysis showed remarkable accuracy – with 92 per cent sensitivity in identifying ME/CFS, which indicates how well the test identifies those who have the disease (a show of true positives) and 98 per cent specificity, which indicates how well it identifies those who do not have the disease.

The researchers also found signs of immune system and inflammation pathways involved in the disease, which may help guide future treatments and identify patients more likely to respond to specific therapies.

A vital tool for diagnosis and treatment

“This is a significant step forward,” said UEA’s Prof Pshezhetskiy. “For the first time, we have a simple blood test that can reliably identify ME/CFS - potentially transforming how we diagnose and manage this complex disease.”

“Additionally, understanding the biological pathways involved in ME/CFS opens the door to developing targeted treatments and identifying which patients might benefit most from specific therapies.

“We hope that the Episwitch® CFS test could become a vital tool in clinical settings, paving the way for more personalised and effective care.”

This research was led by UEA and Oxford BioDynamics in collaboration with The London School of Hygiene & Tropical Medicine and Royal Cornwall Hospitals NHS Trust.

‘Development and validation of blood-based diagnostic biomarkers for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) using EpiSwitch® 3-dimensional genomic regulatory immuno-genetic profiling’ is published in the Journal of Translational Medicine.

ENDS

REFERENCES

^‡ Genetics Discovery Team, et al (2025). Initial findings from the DecodeME genome-wide association study of myalgic encephalomyelitis/chronic fatigue syndrome. medRxiv, Preprint. https://doi.org/10.1101/2025.08.06.25333109  

EDITOR’S NOTES

1/ For more information or to request an interview, please contact the UEA communications office by emailing communications@uea.ac.uk.

Prof Dmitry Pshezhetskiy - D.Pshezhetskiy@uea.ac.uk

Oxford BioDynamics Plc - OBDFinancial@camarco.co.uk

Dr Alexandre Akoulitchev, CSO

Paul Stockdale, CFO

+44 (0)1865 518910

2/ A copy of the paper is available via the following Dropbox link: https://www.dropbox.com/scl/fo/ers5cnflccxypk8vnuqj5/AOSwBM3iCbSgeCX_6eY-Yl0?rlkey=iacml9y98jey6k5bb6i55wk75&st=df06gy26&dl=0

DOI: 10.1186/s12967-025-07203-w

3/ The University of East Anglia (UEA) is a UK Top 25 university (Complete University Guide and HESA Graduate Outcomes Survey). It also ranks in the UK Top 20 for research quality (Times Higher Education REF2021 Analysis) and the UK Top 10 for impact on Sustainable Development Goals. Known for its world-leading research and good student experience, its 360-acre campus has won seven Green Flag awards in a row for its high environmental standards. The University is a leading member of Norwich Research Park, one of Europe’s biggest concentrations of researchers in the fields of environment, health and plant science. www.uea.ac.uk.  

4/ Oxford BioDynamics Plc (AIM: OBD) is an international biotechnology company, advancing personalized healthcare by developing and commercializing precision clinical diagnostic tests for life-changing diseases.

Currently OBD has two commercially available products: the EpiSwitch® PSE (EpiSwitch Prostate Screening test) and EpiSwitch® CiRT (Checkpoint Inhibitor Response Test) blood tests. PSE boosts the predictive accuracy of a PSA test from 55% to 94% when testing the presence or absence of prostate cancer. CiRT is a highly accurate (85%) predictive response test to immuno-oncology checkpoint inhibitor treatments.

The tests are based on OBD's proprietary 3D genomic biomarker platform, EpiSwitch® which enables screening, evaluation, validation and monitoring of biomarkers to diagnose patients or determine how individuals might respond to a disease or treatment.

OBD's clinical smart tests have the potential to be used across a broader range of indications, and new tests are being developed in the areas of oncology, neurology, inflammation, hepatology and animal health.

The Group's headquarters and UK laboratories are in Oxford, UK. Its US operations and clinical laboratory are in Maryland, USA, along with a reference laboratory in

Penang, Malaysia. OBD is listed on the London Stock Exchange's AIM (LSE: OBD). For more information, please visit the Company's website, www.oxfordbiodynamics.com,  X (@OxBioDynamics) or LinkedIn.